FIELD: organic chemistry, medicine, biochemistry, pharmacy.
SUBSTANCE: invention relates to compounds inhibiting activity of hormone-sensitive lipase and represented by structure of the formula: (XXXXIVa)
and the formula (XXXXIVb): 
wherein R1ap and R2ap are chosen independently from (C1-C6)-alkyl, aryl wherein each (C1-C6)-alkyl and aryl can be substituted optionally with one or some substitutes chosen independently from halogen atom, (C1-C6)-alkyl under condition that if R1ap and R2ap are similar then they are not methyl or ethyl, and wherein between substitutes R1ap and R2ap can be a covalent bond optionally, and wherein R5ap, R6ap and R7ap are chosen independently from hydrogen atom and fluorine atom (F), and R4ap is chosen from hydrogen atom, sulfanyl, halogen atom, amino-, nitro-group, (C1-C6)-alkyl, heteroaryl, (C3-C8)-heterocyclyl wherein each among sulfanyl, amino-group, (C1-C6)-alkyl, heteroaryl, (C3-C8)-heterocyclyl can be substituted optionally with one or some substitutes chosen independently from hydroxy-, oxo-group, halogen atom, (C1-C6)-alkyl, aryl, heteroaryl wherein each among (C1-C6)-alkyl, aryl, heteroaryl can be substituted optionally with one or some substituted chosen independently from oxo-group, halogen atom, amino-group, (C1-C6)-alkyl, (C3-C8)-heterocyclyl wherein each among amino-group, (C1-C6)-alkyl, (C3-C8)_heterocyclyl can be substituted optionally with one or some substitutes chosen independently from oxo-group, (C1-C6)-alkyl wherein (C1-C6)-alkyl can be substituted optionally with one or some substitutes chosen independently from oxo-group under condition that R4ap is not methyl. Also, invention relates to a pharmaceutical composition and using these compounds for preparing a medicinal agent used for inhibition of lipolytic activity of hormone-sensitive lipase. Invention describes compounds that can be useful in treatment and prophylaxis of clinical disorders wherein decrease of activity of hormone-sensitive lipase is desirable.
EFFECT: valuable medicinal and biochemical properties of compounds and pharmaceutical composition.
8 cl, 1 tbl, 602 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS | 2004 |
|
RU2337908C2 |
| DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS CONTAINING THEM, OBTAINING AND APPLICATION | 2004 |
|
RU2346938C2 |
| PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES | 2005 |
|
RU2367663C2 |
| PYRAZOLAMINOPIRIMIDINE DERIVATIVES AS LEUCINE-REPEATING KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON DISEASE | 2013 |
|
RU2637948C2 |
| 2-AMINOPYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND METHOD FOR THERAPY | 2001 |
|
RU2250898C2 |
| HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2764243C2 |
| NEW COMPOUND AS A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND | 2019 |
|
RU2785734C1 |
| FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | 2012 |
|
RU2650641C2 |
| OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2815636C1 |
| INHIBITORS OF MATRIX METALLOPROTEINASES | 2004 |
|
RU2370488C2 |
